Global Cardiac Prosthetic Devices Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Product Type (Pacemakers, Heart Valves, Others), By Material (Metal Alloys, Biological Tissue), By End User (Hospitals, Ambulatory Surgical Centers), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 8.45 Billion
CAGR (2026-2031)	8.31%
Fastest Growing Segment	Heart valves
Largest Market	North America
Market Size (2031)	USD 13.64 Billion

Market Overview

The Global Cardiac Prosthetic Devices Market is expected to grow from USD 8.45 Billion in 2025 to USD 13.64 Billion by 2031 at a 8.31% CAGR. Cardiac prosthetic devices encompass a range of implantable or externally applied medical technologies designed to replace or support the function of damaged or diseased heart structures, including heart valves, pacemakers, and ventricular assist devices. The market's expansion is driven by the increasing global prevalence of cardiovascular diseases, the escalating elderly population susceptible to these conditions, and ongoing technological advancements improving device efficacy and patient outcomes. According to the European Heart Rhythm Association's 2025 Atlas on Heart Rhythm Disorders, which utilized 2023 data, the annual median number of pacemakers implanted per million people in European Society of Cardiology member countries was 739.

This demand contributes to a substantial medical technology sector, with MedTech Europe estimating the overall European medical technology market at approximately €173 billion in 2025, wherein cardiology constitutes the second-largest sector globally. However, a significant impediment to market expansion remains the stringent and protracted regulatory approval processes, which can increase development costs and delay market entry for innovative cardiac prosthetic devices.

Key Market Drivers

Rising Cardiovascular Disease Burden Drives Prosthetic Demand
The increasing prevalence of cardiovascular diseases acts as a primary driver for the global cardiac prosthetic devices market. Global demographic shifts and changing lifestyles contribute to a rising incidence of heart-related conditions, necessitating prosthetic implants to restore or support cardiac function. This expanding patient burden is significant, with an estimated 650 million people living with cardiovascular disease across the world, a figure consistently rising according to the British Heart Foundation in their 'Global Cardiovascular Disease Factsheet' published in July 2026. This large and growing patient pool directly fuels demand for a broad spectrum of cardiac prosthetic solutions, from advanced pacemakers to sophisticated heart valves and ventricular assist devices.

Technological Innovation and Investment Fuel Cardiac Prosthetics Growth
Technological advancements in cardiac prosthetic devices represent another substantial market driver, facilitating the development of more effective and safer treatment options. Continuous innovation focuses on improving device longevity, minimizing invasiveness, and enhancing patient recovery. This commitment to progress is underscored by industry investments; for instance, Medtronic's 'FY2026 Annual Report', published in June 2026, indicated the company's R&D expense was US$2.873 billion for the fiscal year ending April 24, 2026, representing 7.9% of net sales. Such investments drive the creation of miniaturized devices, advanced materials, and smart implants with remote monitoring capabilities. These continuous enhancements in device technology and clinical utility attract both patients and healthcare providers, further expanding the market. Overall, the Cardiac portfolio of Medtronic alone achieved $14.0 billion in revenue, reflecting a 12% increase as reported for the fiscal year ending April 24, 2026, according to the same Medtronic 'FY2026 Annual Report'.

Download Free Sample Report

Key Market Challenges

Regulatory Delays Impede Market Expansion and Increase Costs
The stringent and protracted regulatory approval processes represent a significant challenging factor for the "Global Cardiac Prosthetic Devices Market". These complex regulatory pathways directly impede market expansion by substantially increasing development costs and considerably delaying the market entry of innovative cardiac prosthetic devices.

Regulatory Lag in Europe Underscores Need for MDR/IVDR Revisions
For instance, according to MedTech Europe's "Facts & Figures 2026" report, published in October 2026, the spending on medical technology in Europe grew by only 1.8% in 2025, which is notably below the decade average of approximately 5.6%. The report explicitly links this slowdown to a regulatory system that has not kept pace with innovation, noting that the revision of the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) is crucial to restore speed and predictability. This prolonged regulatory environment necessitates extensive documentation, multiple review cycles, and substantial financial investment before a product can reach patients, thereby restricting the pace at which advanced cardiac care solutions become available. This directly dampens innovation and reduces the competitiveness of the medical technology sector within key markets.

Key Market Trends

Shift toward transcatheter and minimally invasive cardiac prosthetic devices
The global cardiac prosthetic devices market is significantly shaped by the shifting preference towards transcatheter and minimally invasive approaches. This trend is driving innovation in device design, focusing on smaller, more flexible implants that can be delivered without open-heart surgery, thereby reducing patient trauma and recovery times. The adoption of these less invasive procedures broadens patient eligibility, particularly for elderly or high-risk individuals who may not be candidates for traditional surgical interventions. This procedural evolution supports market expansion as healthcare providers increasingly favor methods that improve patient outcomes and operational efficiency. According to Edwards Lifesciences' "Fourth Quarter Results" published in February 2026, the company expects its Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue to grow 35-45% to $740-$780 million for the full year 2026, highlighting the rapid growth in these advanced procedural categories.

Digital health integration and remote monitoring in cardiac prosthetics
Another pivotal trend influencing the market is the integration of digital health and remote patient monitoring capabilities into cardiac prosthetic devices. This trend allows for continuous oversight of device function and patient physiological data from outside clinical settings, enhancing proactive care management and potentially reducing hospital readmissions. Devices equipped with these features offer improved diagnostic accuracy and enable clinicians to adjust therapies remotely, fostering a more connected and responsive healthcare ecosystem. This integration also contributes to improved patient adherence and early detection of potential complications, which can lead to timelier interventions. According to Boston Scientific's "Q3 2026 Earnings Call Highlights" published in October 2026, the company's Cardiac Rhythm Management sales declined 2% in the third quarter, partly due to disruption involving remote-monitoring systems during a cybersecurity incident, underscoring the critical reliance on these integrated technologies.

Segmental Insights

Drivers of Rapid Growth in the Heart Valves Segment
The heart valves segment is the fastest-growing within the Global Cardiac Prosthetic Devices Market. This significant expansion is primarily driven by the escalating prevalence of valvular heart diseases, largely attributable to an aging global demographic and rising cardiovascular risk factors. Furthermore, rapid technological advancements, particularly in transcatheter valve replacement procedures, offer less invasive alternatives to traditional open-heart surgery. These innovations improve patient outcomes by reducing procedural risks and recovery times, making them suitable for a broader patient cohort. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have supported the adoption of these innovative solutions by expanding indications, further propelling segment growth.

Regional Insights

North America’s Market Leadership: Advanced Infrastructure, Regulation, and Innovation
North America leads the global cardiac prosthetic devices market due to its highly advanced healthcare infrastructure and a high incidence of cardiovascular diseases. The region benefits from substantial healthcare expenditure, robust reimbursement policies, and the swift adoption of innovative medical technologies. Furthermore, the presence of major market players, coupled with strong regulatory frameworks established by bodies like the U.S. Food and Drug Administration (FDA), facilitates extensive research and development and accelerates the market entry of new prosthetic devices. This environment fosters technological superiority and continuous product advancements.

Recent Developments

• In May 2025, BiVACOR, a medical device company, announced that its titanium Total Artificial Heart received Breakthrough Device Designation from the U.S. Food and Drug Administration. This designation recognizes the potential for the BiVACOR Total Artificial Heart to significantly improve outcomes for adults with severe biventricular or univentricular heart failure as a bridge to transplant, particularly when other therapies are insufficient. The development follows positive early results from an FDA Early Feasibility Study, which began in July 2024, supporting the expansion of the trial.
• In October 2024, Edwards Lifesciences announced significant breakthrough research findings from its EARLY-TAVR trial, impacting the transcatheter aortic valve replacement segment of the cardiac prosthetic devices market. The study demonstrated that asymptomatic patients with severe aortic stenosis who underwent early transcatheter aortic valve replacement experienced superior clinical outcomes compared to those receiving guideline-recommended clinical surveillance. With a median follow-up of 3.8 years, data indicated that early TAVR intervention prevented unpredictable symptom progression and a rapid decline in quality of life, alongside a numerically lower rate of stroke for patients.
• In May 2024, Boston Scientific presented positive results from a pivotal clinical trial for its modular cardiac rhythm management system, a key innovation for implantable cardiac devices. This system, designed for patients at risk of sudden cardiac death from ventricular arrhythmias, combines a leadless pacemaker with an implantable defibrillator that communicate wirelessly. The trial successfully met all pre-specified six-month safety and effectiveness endpoints, including high rates of wireless device communication and complication-free leadless pacemaker implantation. The company anticipates receiving FDA approval for this advanced system in 2025, further expanding treatment options for cardiac rhythm disorders.
• In January 2024, Medtronic received CE Mark approval for its Micra AV2 and Micra VR2 miniature, leadless pacemakers, which are integral to the global cardiac prosthetic devices market. These next-generation devices offer enhanced features, including extended battery life, projected to be nearly 16 and 17 years respectively, and simplified programming. The Micra AV2 and Micra VR2 aim to provide patients with the benefits of leadless pacing, such as a reduction in complications compared to traditional pacemakers. Additionally, these leadless pacemakers are equipped with remote monitoring capabilities, which facilitate ongoing patient management and may reduce the need for frequent hospital visits.

Key Market Players

• Abbott Laboratories
• Medtronic plc
• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• LivaNova PLC
• Biotronik SE & Co. KG
• Lepu Medical Technology
• Meril Life Sciences
• Colibri Heart Valve
• Siemens Healthineers

By Product Type	By Material	By End User	By Region
Pacemakers Heart Valves Others	Metal Alloys Biological Tissue	Hospitals Ambulatory Surgical Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Prosthetic Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Prosthetic Devices Market, By Product Type:

• Pacemakers
• Heart Valves
• Others

• Cardiac Prosthetic Devices Market, By Material:

• Metal Alloys
• Biological Tissue

• Cardiac Prosthetic Devices Market, By End User:

• Hospitals
• Ambulatory Surgical Centers

• Cardiac Prosthetic Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE